OPKO Health, Inc. (NYSE:OPK), reported that its licensee, TESARO, Inc.
(Nasdaq:TSRO), has submitted a New Drug Application (NDA) to the U.S.
Food and Drug Administration (FDA) for approval of oral rolapitant, an
OPKO Health, Inc. (NYSE:OPK)
Q2 2014 Earnings Conference Call
August 12, 2014 8:30 am ET
Steven D. Rubin - EVP, Administration
Phillip Frost - Chairman and CEO
Charles W. Bishop - CEO of OPKO Renal Division
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Opko+Health+%28OPK%29+Reports+No+Statistically+Significant+Data+Observed+in+Lagova+Phase+2+as+Pediatric+GHD+Treatment/9613634.html for the full story.
OPKO Health, Inc. (NYSE: OPK), a multinational biopharmaceutical and
diagnostics company, yesterday hosted a webcast presenting outstanding interim
six-month results from a Phase 2 study of its long-acting human growth hormone
product Lagova to...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Opko Health Inc (OPK):